**Name of Journal: *World Journal of Diabetes***

**ESPS Manuscript NO: 30121**

**Manuscript Type: Original Article**

***Case Control Study***

**Association of *NFKB1* gene polymorphism (rs28362491) with levels of inflammatory biomarkers and susceptibility to diabetic nephropathy in Asian Indians**

GautamA *et al. NFKB1* gene polymorphism and diabetic nephropathy

**Amar Gautam, Stuti Gupta, Mohit Mehndiratta, Mohini Sharma, Kalpana Singh, Om P Kalra, Sunil Agarwal, Jasvinder K Gambhir**

**Amar Gautam, Om P Kalra, Sunil Agarwal,** Department of Medicine, University College of Medical Sciences (University of Delhi) and G.T.B. Hospital, Delhi 110095, India

**Stuti Gupta, Mohit Mehndiratta, Mohini Sharma, Kalpana Singh, Jasvinder K Gambhir,** Molecular Diagnostic Laboratory, Department of Biochemistry, University College of Medical Sciences (University of Delhi) and G.T.B. Hospital, Delhi 110095, India

**Author contributions:** Gautam A and Gupta G contributed equally to this article; Gautam A, Gupta G, Sharma M and Singh K performed sample collection, majority of experiments, analyzed data and wrote manuscript; Mehndiratta M, Kalra OP, Agarwal S and Gambhir JK contributed to conceptual and study design, data analysis and interpretation, as well as manuscript writing.

**Institutional review board statement:** The protocol of the present study was reviewed and approved by Institutional Ethics Committee for Human Research, Delhi University, and UCMS and GTB Hospital, Delhi.

**Informed consent statement:** Informed consent was obtained from the all recruited subjects. They were briefed on the purpose of the study and its implication prior to donating peripheral blood.

**Conflict-of-interest statement:** No conflict of interest exists for this study.

**Data sharing statement:** No data sharing as this manuscript and the data were not published elsewhere.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

 **Manuscript source:** Invited manuscript

**Correspondence to:Jasvinder K Gambhir, PhD, Professor,** Molecular Diagnostic Laboratory, Department of Biochemistry, University College of Medical Sciences (University of Delhi) and G.T.B. Hospital, Dilshad Garden, Delhi 110095, India. jassigambhir@yahoo.co.in

**Telephone:** +91-98-11641277

**Received:** September 12, 2016

**Peer-review started:** September 19, 2016

**First decision:** October 21, 2016

**Revised:** December 6, 2016

**Accepted:** December 27, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate the association of *NFKB1* gene-94 ATTG insertion/deletion (rs28362491) polymorphism with inflammatory markers and risk of diabetic nephropathy in Asian Indians.

 ***METHODS***

A total of 300 subjects were recruited (100 each), normoglycemic, (NG); type 2 diabetes mellitus (T2DM) without any complications (DM) and T2DM with diabetic nephropathy [DM-chronic renal disease (CRD)]. Analysis was carried out by PCR-RFLP and ELISA. Pearson’s correlation, analysis of variance and logistic regression were used for statistical analysis.

***RESULTS***

The allelic frequencies of-94 ATTG insertion/deletion were 0.655/0.345 (NG), 0.62/0.38 (DM) and 0.775/0.225 (DM-CRD). The -94 ATTG ins allele was associated with significantly increased levels of urinary monocyte chemoattractant protein-1 (uMCP-1); uMCP-1 (*P* = 0.026) and plasma tumor necrosis factor-alpha (TNF-α); TNF-α (*P* = 0.030) and almost doubled the risk of diabetic nephropathy (OR = 1.91, 95%CI: 1.080-3.386, *P* = 0.025).

***CONCLUSION***

-94 ATTG ins/ins polymorphism might be associated with increased risk of developing nephropathy in Asian Indian subjects with diabetes mellitus.

**Key words:** Diabetic nephropathy; Inflammation;*NFKB1* -94 ATTG ins/del polymorphism; Urinary monocyte chemoattractant protein-1; Tumor necrosis factor-alpha

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Type 2 diabetes mellitus (T2DM) is considered as long standing inflammatory disease. Diabetic nephropathy (DN) is the most common micro-vascular complication of T2DM.Pro-inflammatory cytokines likeMonocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) plays a crucial role in the pathogenesis of DN. Therefore we investigated -94 ins/del ATTG polymorphism in *NFKB1* gene and its association with the risk of DN in Asian Indians. -94 ins/del ATTG single nucleotide polymorphism was found to increase the urinary MCP-1 and plasma TNF-α levels. Our findings open a new area of research to explore that -94 ins/del ATTG may be considered as genetic markers for early detection of diabetic patients who are at greater risk of development of nephropathy.

Gautam A, Gupta S, Mehndiratta M, Sharma M, Singh K, Kalra OP, Agarwal S, Gambhir JK. Association of *NFKB1* gene polymorphism (rs28362491) with levels of inflammatory biomarkers and susceptibility to diabetic nephropathy in Asian Indians. *World J Diabetes* 2016; In press

**INTRODUCTION**

Chronic renal disease (CRD) is an intricate pathological process, often leading to end stage renal disease (ESRD). The causes of CRD are quite multi-factorial ranging from infections to heredity, but type 2 diabetes mellitus (T2DM) is the major culprit amongst them[1]. In spite of the improvement in our knowledge about the etiopathogenesis of diabetic nephropathy (DN), the intricate mechanisms leading to the development of renal injury from chronic hyperglycemia are not yet fully understood. DN has been considered a micro-vascular complication of hyperglycemia, but various clinical and experimental studies have observed that there is a close link between hyperglycemia, inflammation and oxidative stress (OS)[2]. OS may also be involved in promoting a low grade systemic inflammation in patients with T2DM and vice versa[3]. Nuclear factor-kappa B (NF-κB) activation through hyperglycemia induced OS may lead to increased concentration of inflammatory cytokines[4].

NF-κB was identified as a transcription factor which controls the expression of numerous genes affecting immune response, inflammation, cell-growth control, apoptosis and therefore, is an emerging candidate for studies on the pathogenesis of inflammatory diseases including DN. There are five members of the NF-κB family in mammals: NF-κB1: p105/p50, NF-κB2: p52/p100, RelA: p65, RelB, and c-Rel. The chief form of NF-κB is a hetero-dimer of the p50 and p65/RelA subunits, encoded by the *NFKB1* and *RelA* gene. Normally, inactive NF-κB is found in the cytoplasm bound to IkBs, which are specific inhibitor proteins in cytoplasm. Cell when exposed to a variety of proinflammatory stimuli leads to the quick phosphorylation followed by ubiquitinylation, and finally proteolytic breakdown of I-kB. This causes transfer of NF-κB in nucleus and thus leading to increased transcription of gene[5]. NF-κB transcriptionally regulates many downstream proinflammatory genes, mainly including monocyte chemoattractant protein-1 (*MCP-1*), tumor necrosis factor-alpha (*TNF-α*)[6].

MCP-1 is an important proinflammatory chemokine which affects the recruitment and function of monocyte[7]. MCP-1 is synthesized in response to a various proinflammatory stimuli by kidney cell[8]. A study done by Wada *et al*[9] in 2000 has shown that expression of MCP-1 increases in inflammation induced kidney diseases including DN. Urinary MCP-1 (uMCP-1) is a potential biomarker for renal damage[10]. Hyperglycemia induced secretion of abundant MCP-1 from renal parenchymal cells, attract monocytes into the kidney stimulating myofibroblast-like properties in mesangial cells. Kidney macrophages when exposed to MCP-1 in diabetic milieu promotes activation of macrophage. Thus, leading to release of reactive oxygen species (ROS), various pro-inflammatory cytokines and profibrotic growth factors[11,12]. Thus, resulting in exaggerated inflammation that leads to renal injury through proliferation of myofibroblast, augmented production of extracellular matrix by mesangial cells and fibroblasts.

TNF-α is a well known proinflammatory cytokine associated with systemic inflammation[13,14]. It is produced predominantly by macrophages and monocytes[13,14]. TNF-α acts *via* NF-κB signaling and mediates the transcription of various cytokines performing roles in cell survival, proliferation, inflammatory responses, cell adhesion and inflammation[15]. A study has shown that there is upregulation of TNF-α expression in glomeruli of diabetic rats[16]. TNF-α is well acknowledged to cause damage to renal cells by enhancing renal hyperthrophy, hemodynamic imbalance, albumin permeability[17]. The harmful effects of these responses lead to the development of renal disease in patients with T2DM, hence resulting in the progression of renal failure.

In addition to poor glycemic control, OS and inflammation; genetic factors seem to be main determinants of DN in terms of both occurrence and severity[18]; however the genetic mechanism causing DN is still unexplored. In our knowledge, there is no study available regarding the polymorphisms of *NFKB1* and their correlation with levels of uMCP-1 and plasma TNF-α. We have reported[19] increased uMCP-1, plasma TNF-α levels in subjects with DN when compared to subjects with T2DM without nephropathy and observed a positive correlation between uMCP-1 and plasma TNF-α[20]. We have also highlighted that DN is associated with *TNFA* gene single nucleotide polymorphism (SNP)[20]. In recent times, a new functional *NFKB1* promoter SNP consisting of a insertion/deletion (-94ins/del ATTG) (rs28362491) has been identified which can elicit a regulatory effect on the NFKB1 gene[21]. Since above mentioned polymorphism has been associated with various inflammatory diseases, autoimmune diseases and cancers[22], therefore, it is worthwhile to further investigate the association of -94 ins/del ATTG *NFKB1* gene SNP with levels of uMCP-1, plasma TNF-α and nephropathy risk in subjects with T2DM.

**MATERIALS AND METHODS**

***Study design***

The present study comprises of total 300 subjects visiting Nephrology Outpatient Clinic and Medicine OPD at University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi. Subjects were divided into three groups of 100 each namely; Group 1: Normoglycemic (NG), Group 2: Subjects with T2DM for ≥ 10 years without nephropathy (DM), Group 3: Subjects with T2DM for ≥ 5 years with nephropathy (DM-CRD). T2DM was diagnosed according to revised ADA criteria[23]. Detailed clinical history and physical examination were recorded. Blood pressure (BP) of subjects was estimated using sphygmomanometer in the sitting position after a resting period of 10 min. The estimated glomerular filtration rate (eGFR) was measured by Modification of Diet in Renal Disease Abbreviated Equation (MDRD)[24].

The presence of micro-albuminuria in T2DM subjects was detected by Urine Test 11 MAU dipstick (Piramal Diagnostic, sensitivity: 10-15 mg/dL), and all participants having proteinuria and micro-albuminuria were clubbed in Group 3. All participants with nephropathy were in pre-dialysis stage. Normoglycemic (Group 1) subjects were recruited from employees of UCMS and GTB Hospital with the following criteria: (1) they did not have of diabetes mellitus (fasting plasma glucose < 100 mg% or postprandial glucose < 140 mg% or HbA1c < 5.7%) according to ADA criteria; (2) there was no presence of diabetes in their first or second degree relatives; and (3) they had normal BP, with systolic and diastolic BP not > 120 mmHg and 80 mmHg[25].

To circumvent any possible confounding factors, patients having renal disorders (hypertensive nephropathy, chronic glomerular nephritis, chronic interstitial disease, ischemic nephropathy, obstructive nephropathy), acute and chronic infections, congestive heart failure, malignancy and liver disorder were not included into the study. All subjects in Group 3 had retinopathy; but participants with macro-vascular complications like coronary artery disease and stroke were not included into the study. Patients taking renin-angiotension aldosterone system inhibitors, aspirin and vitamin D analogues were advised to discontinue these drugs for a period of a week before inclusion in the study since they have been found to influence the synthesis of uMCP-1 and TNF-α. However, patients were prescribed beta-blockers to control BP in that duration of one week. The Institutional Ethics Committee for Human Research approved the protocol of this study (approval number-UCMS/IEC-HR/2010/10). Prior to the inclusion into the present study, informed written consent was taken from all participants.

***Biochemical parameters***

Under aseptic conditions fasting venous blood samples were withdrawn and collected into EDTA and fluoride vials. For glycosylated hemoglobin (HbA1c) 200 µL whole blood was preserved at 4 ºC-8 ºC and processed within one week of collection. Blood samples collected in EDTA vial was subjected to centrifugation at 3000 rpm for 10 min in order to separate the plasma. Early morning first mid-stream urine sample was collected and stored in aliquots at -20 °C for estimation of MCP-1, albumin and creatinine.

Routine investigations such as fasting and post-prandial plasma glucose, urea, creatinine and uric acid were carried out using commercially available kits on autoanalyser (Olympus AU-400). HbA1c was estimated by ion-exchange resin chromatography using commercially available kits (Fortress, United Kingdom). Urinary protein excretion was expressed as albumin to creatinine ratio.

***Markers of inflammation***

uMCP-1 (Weldon, California; sensitivity less than 7.8 pg/mL) and plasma TNF-α (Diaclone, France; sensitivity less than 8 pg/mL) were estimated by commercially available ELISA kit.

***DNA extraction and polymorphism genotyping***

Cellular DNA of every individual was extracted from 200 µL EDTA-anticoagulated peripheral blood sample by means of DNA isolation kit (Zymo research, United States). The polymerase chain reaction was carried out in Thermocycler (Eppendorf Mastercycler Gradient-5331). In brief, 0.1 µg of DNA was amplified in a reaction mixture of 20 µL containing 0.5 µmol/L each of the following primer pairs (Forward 5’-TGGGCACAAGTCGTTTATGA-3’ and Reverse 5’CTGGAGCCGGTAGGGAAG-3’). The reaction mixture also contained 0.5 mmol/L (dNTP mix), 2 µL (10 × PCR buffer) and 2.0 units Taq DNA polymerase, 2 mmol/L MgCl2. The PCR protocol consist an initial temperature of 94 ºC (5 min) followed by 35 cycles of amplification (30 s at 94 ºC, 45 s at 59 ºC, and extension for 1 min at 72 ºC). Final extension step was carried out for 2-min at 72 ºC[22].

For the study of the -94 insertion/deletion ATTG SNP in *NFKB1*, PCR product (281/285 bp) was subjected to fast digestion with restriction enzyme *PfIMI*. PCR products was treated with enzyme *PfIMI* in at 37 ºC for 1 hour and inactivated at 65 °C for 20 min. The insertion allele (ins) was cut down into two fragments of 45 bp and 240 bp by *PfIMI* restriction enzyme. But, there was no cleavage at the deletion allele (del) that has only one ATTG at its promoter[22]. The bands of digested products were visualized in 2% agarose gel electrophoresis stained with ethidium bromide.

***Statistical analysis***

Demographic profiles and routine investigation was compared by *χ*2 and Student’s *t*-test and one-way ANOVA was used. To associate all the study groups with genotype two-way ANOVA followed by *post-hoc* Tukey’s test was used. For association of genotypes with uMCP-1 and plasma TNF-α levels, analysis of variance was used. Logistic regressions was used to evaluate the risk of development of DN at the single SNP level. Power of sample size keeping 5% significance level and 80% power was calculated by genetic power calculator. A *P* value < 0.05 was considered statistically significant (two-tailed). All statistical tests were performed using SPSS version 20.

**RESULTS**

***Characteristics of the study population***

Biochemical and demographic parameters of the various study groups are shown in Table 1. There was no difference in sex distribution and BMI within all the three study groups. The subjects of Group 2 (DM) and Group 3 (DM-CRD) were older than Group 1 (NG) subjects; however the period of diabetes was more in Group 2 (DM) than Group 3 (DM-CRD) which was as per our selection criteria. Incidence of hypertension was significantly higher in Group 2 (DM) and Group 3 (DM-CRD) participants as suggested by raised SBP and DBP (*P* < 0.001) when compared to NG. Poor glucose control was observed in DM-CRD as compared to DM as suggested by significantly higher (*P* < 0.001) fasting, postprandial plasma glucose and HbA1c. Renal function tests suggested that blood urea, plasma creatinine, and uric acid were significantly higher (*P* < 0.001) and eGFR was decreased (*P* < 0.001) in Group 3 (DM-CRD) as compared to Group 2 (DM).

***Distribution of ins/del in study population***

The allele frequencies and genotype of the NFKB1 gene for -94 insertion/deletion ATTG SNP in various study groups are shown in Table 2. The distribution percentage of ins/ins, ins/del, del/del genotypes in Group 1 (NG), Group 2 (DM) and Group 3 (DM-CRD) (expressed in percentage) were 41%, 49% and 10%; 38%, 48% and 14%; and 61%, 33% and 6% respectively. The frequency of del/del genotype was significantly lower (*P* < 0.001) in Group 3 (DM-CRD) as compared to Group 2 (DM). However, allele frequencies of -94 insertion/deletion ATTG were 65.5%/34.5% in Group 1 (NG), 62%/38% in Group 2 (DM) and 77.5%/22.5% in Group 3 (DM-CRD).

***Relationship between the -94 ins/del AGGT SNP with inflammatory markers and disease risk***

Correlation of -94 ins/del AGGT SNP with levels of uMCP-1 and plasma TNF-α have been studied and the results are shown in Table 3. The -94 ins allele were associated with increased levels of uMCP-1 (*P* = 0.026) and plasma TNF-α (*P* = 0.030) in the disease study groups, *i.e*., Group 2 (DM), Group 3 (DM-CRD).

The associations at the level of genotype is shown in Table 4. Highly significant association was observed for -94 ins/del AGGT polymorphism in subjects with Group 3 (DM-CRD) in comparison to Group 1 (NG); *P* = 0.022. In our present study, -94 ins SNP was found to increase risk for the development of DN by 1.91-fold in subjects with diabetes (OR = 1.91, 95%CI: 1.080-3.386, *P* = 0.025).

**DISCUSSION**

Polymorphism in the NFKB1 promoter region at position -94 ins/del AGGT has been correlated with many long standing inflammatory diseases like autoimmune diseases such as rheumatoid arthritis, asthma, AIDS, cancers and various diabetic complications[26,27]. Our study is the first to report the association of above mentioned polymorphism with DN in North Indian population. In the current study, we observed that the frequency distribution of ins/del is maximum in NG and DM subjects followed by ins/ins, with least distribution of del/del in the same. However the trend was different in DM-CRD subjects with respect to ins/del genotype which was less as compared to ins/ins this group. The frequency of different genotypes observed in the present study were in accordance with studies on NFKB1 polymorphism in healthy volunteer in different ethnic population like Turkish[22], Caucasians[28], English[29], Polish[30]. But our results were not in agreement with healthy Chinese population[28]. When our findings were compared with studies on inflammatory diseases like cancer, they are in accordance with a studies conducted in Asian by Huo *et al*[31] and Zhou *et al*[32]. However our results were in contrast with a genomic study on cancer conducted by Yang *et al*[28] in 2014. The dissimilarity of results could be due to diverse geographical distribution and ethnicity between our study and theirs was different, which could result in diverse genetic background.

Latest evidence has shown that the production of MCP-1 by kidney affected by diabetes along with TNF-α is a major cause of inflammation, renal injury and fibrosis in DN[10,17]. The present study is the foremost one to document the correlation of -94 ins/del AGGT SNP with levels of inflammatory markers namely uMCP-1 and plasma TNF-α in DN from North Indian patients. In our previous study, we have observed that plasma TNF-α and uMCP-1levels were significantly raised in patients with T2DM and so more in patients with DN[19]. To explicate the role of NFKB1 gene SNP in the development of DN, -94 ins/del AGGT SNP were analyzed in various study, *i.e.*, Group 2 (DM) and Group 3 (DM-CRD) and further correlated with measured inflammatory markers like uMCP-1 and plasma TNF-α levels. Interestingly, this study has also shown that ins allele was significantly associated with increased urinary MCP-1 and plasma TNF-α levels in NG as well as patient groups. However, there is no report in literature to compare our results.

A recent study has shown that TNF-α stimulates the MCP-1 production *via* NF-κB signalling pathway in rat astrocyte cultures[33]. TNF-α was found to increase p65 and phosphorylated p65 levels in nuclear extracts of rat astrocytes, hence augmenting MCP-1 levels[33]. This supports our finding that increased levels of TNF-α are associated with increased levels of uMCP-1.

Genetic variations are known to play a vital role in determining risk of DN. A number of studies have investigated the relationship of ins allele of -94 ins/del AGGT polymorphism with various inflammatory diseases. Till date not a single study has tried to evaluate the association between this polymorphism and DN risk. Our study is first to document that patients with T2DM having ins/ins genotype were found to have increased risk of developing nephropathy. Latest studies have reported that p50 null mice have a significantly reduced inflammatory response in various models of inflammation such as asthma[34], arthritis[35], and autoimmune encephalomyelitis[36]. A similar study conducted in sporadic colorectal cancer (CRC)[37] and epithelial ovarian cancer (EOC)[31] has supported our findings which suggested that ins/ins genotype contribute to significantly increased risk of CRC and EOC. The probable mechanism of -94 ins/del AGGT polymorphism leading to increased risk of developing DN is explained in Figure 1. In almost all cell types, NF-κB complexes are typically localized in the cytoplasm where they bind to IKB inhibitory proteins. However, stimulation with hyperglycemia induced ROS and TNF-α leads to rapid phosphorylation of IKB *via* I-kB kinases complex which is then degraded by ubiquitin-proteosome pathway. On the other hand, simultaneously -94 ins/del AGGT polymorphism might lead to increased synthesis of p50 mRNA. Hence there will be increased production of p50/p65 hetrodimer complex which is a well known proinflammatory molecule, since p50/p65 hetrodimer acts on its downstream proinflammatory targets *viz*: MCP-1 and TNF-α, leading to over production of MCP-1 and TNF- α. Thus, there occurs a viscous cycle, *i.e*., MCP-1 is a positive regulator of TNF-α and vice versa. The above mentioned probable hypothesis might lead to increased risk of developing renal damage in T2DM. However results of a recent study from China[38] in bladder cancer is in contradiction to our findings which could be due to ethnic and geographical differences. Furthermore, the sample size of our study was fairly small than aforementioned bladder cancer study.

The results of the current study suggest that the NFKB1 promoter -94 ins/del AGGT SNP is associated with increased possibility of developing nephropathy in patients with diabetes. This SNP may be considered as genetic markers for susceptibility to develop nephropathy in patients with T2DM. The limitation of the study is the small sample size. Therefore, further evaluation is necessary in big sample size to look for the possibility of this polymorphisms as potential genetic markers in the near future. This would help to identify patients with Type 2 diabetics who may be at higher risk of developing nephropathy.

**ACKNOWLEDGEMENTS**

This study was financially supported by Indian Council of Medical Research and Postgraduate Research Grant, University College of Medical Sciences, New Delhi. The authors are thankful to the Department of Biostatistics and Medical Informatics, University College of Medical Sciences, Delhi for statistical analysis

**COMMENTS**

***Background***

Type 2 diabetes mellitus (T2DM) is considered as a long standing inflammatory disease. Nuclear factor-kappa B (NF-κB) controls the expression of numerous genes affecting inflammation, immune response. Immunogenic and inflammatory cytokines like monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) plays a crucial role in the pathogenesis of micro-vascular complication of T2DM, *i.e*., diabetic nephropathy (DN) and clinical outcome.

***Research frontiers***

In spite of the present advances in our knowledge about the etiopathogenesis of DN, the intricate mechanisms leading to the development of renal injury from chronic hyperglycemia are not yet fully understood. *NFKB1* promoter polymorphism -94 ins/del ATTG has been associated with inflammatory diseases, autoimmune diseases and cancers. However, its role in the development of T2DM and DN has not been explored till date. The authors hypothesized that the -94 ins/del ATTG polymorphism would affect the levels of urinary MCP-1 and plasma TNF-α and therefore might be culprit in developing DN.

***Innovations and breakthroughs***

The authors have recently reported that -94 ATTG ins allele was associated with significantly increased levels of urinary MCP-1, plasma TNF-α and was found to increase risk for the development of DN by 1.91-fold in subjects with diabetes

***Applications***

-94 ins/del AGGT polymorphisms can be considered as genetic marker foridentifying those more susceptible and provide suitable interventions to delay the progression of DN. This study provides a ground for the development of newer anti-inflammatory therapeutic agents that may have potential to affect primary mechanisms contributing to the pathogenesis of DN

***Terminology***

DN: Diabetic nephropathy; NF-κB: Nuclear factor-kappa B; *NFKB1*: Nuclear factor-kappa B1 gene; T2DM: Type 2 diabetes mellitus; TNF-α: Tumor necrosis factor-alpha; uMCP-1: Urinary Monocyte chemoattractant protein-1.

***Peer-review***

The manuscript is well informative.

**REFERENCES**

1 **Levey AS**, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2005; **67**: 2089-2100 [PMID: 15882252]

2 **Pan HZ**, Zhang L, Guo MY, Sui H, Li H, Wu WH, Qu NQ, Liang MH, Chang D. The oxidative stress status in diabetes mellitus and diabetic nephropathy. *Acta Diabetol* 2010; **47** Suppl 1: 71-76 [PMID: 19475334 DOI: 10.1007/s00592-009-0128-1]

3 **Arnalich F**, Hernanz A, López-Maderuelo D, Peña JM, Camacho J, Madero R, Vázquez JJ, Montiel C. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. *Horm Metab Res* 2000; **32**: 407-412 [PMID: 11069205 DOI: 10.1055/s-2007-978662]

4 **Esposito K**, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation* 2002; **106**: 2067-2072 [PMID: 12379575]

5 **Karin M**, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. *Annu Rev Immunol* 2000; **18**: 621-663 [PMID: 10837071 DOI: 10.1146/annurev.immunol.18.1.621]

6 **Barnes PJ**, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 1997; **336**: 1066-1071 [PMID: 9091804 DOI: 10.1056/NEJM199704103361506]

7 **Gu L**, Tseng SC, Rollins BJ. Monocyte chemoattractant protein-1. *Chem Immunol* 1999; **72**: 7-29 [PMID: 10550927]

8 **Rovin BH**, Yoshiumura T, Tan L. Cytokine-induced production of monocyte chemoattractant protein-1by cultured human mesangial cell. *J Immunol* 1992; **148**: 2148-2153

9 **Wada T**, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. *Kidney Int* 2000; **58**: 1492-1499 [PMID: 11012884 DOI: 10.1046/j.1523-1755.2000.00311.x]

10 **Tesch GH**. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. *Am J Physiol Renal Physiol* 2008; **294**: F697-F701 [PMID: 18272603 DOI: 10.1152/ajprenal.00016.2008]

11 **Ihm CG**, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha DR, Ha H. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. *Nephron* 1998; **79**: 33-37 [PMID: 9609459]

12 **Banba N**, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. *Kidney Int* 2000; **58**: 684-690 [PMID: 10916091 DOI: 10.1046/j.1523-1755.2000.00214.x]

13 **Sugimoto H**, Shikata K, Wada J, Horiuchi S, Makino H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. *Diabetologia* 1999; **42**: 878-886 [PMID: 10440132]

14 **Pamir N**, McMillen TS, Kaiyala KJ, Schwartz MW, LeBoeuf RC. Receptors for tumor necrosis factor-alpha play a protective role against obesity and alter adipose tissue macrophage status. *Endocrinology* 2009; **150**: 4124-4134 [PMID: 19477937 DOI: 10.1210/en.2009-0137]

15 **Luo SF**, Fang RY, Hsieh HL, Chi PL, Lin CC, Hsiao LD, Wu CC, Wang JS, Yang CM. Involvement of MAPKs and NF-kappaB in tumor necrosis factor alpha-induced vascular cell adhesion molecule 1 expression in human rheumatoid arthritis synovial fibroblasts. *Arthritis Rheum* 2010; **62**: 105-116 [PMID: 20039412 DOI: 10.1002/art.25060]

16 **Nakamura T**, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. *Diabetes* 1993; **42**: 450-456 [PMID: 8094359]

17 **Rivero A**, Mora C, Muros M, García J, Herrera H, Navarro-González JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. *Clin Sci* (Lond) 2009; **116**: 479-492 [PMID: 19200057 DOI: 10.1042/CS20080394]

18 **Makuc J**, Petrovič D. A review of oxidative stress related genes and new antioxidant therapy in diabetic nephropathy. *Cardiovasc Hematol Agents Med Chem* 2011; **9**: 253-261 [PMID: 21902657]

19 **Gupta S**, Gambhir JK, Kalra O, Gautam A, Shukla K, Mehndiratta M, Agarwal S, Shukla R. Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population. *J Diabetes Complications* 2013; **27**: 548-552 [PMID: 24012111 DOI: 10.1016/j.jdiacomp.2013.07.005]

20 **Gupta S**, Mehndiratta M, Kalra S, Kalra OP, Shukla R, Gambhir JK. Association of tumor necrosis factor (TNF) promoter polymorphisms with plasma TNF-α levels and susceptibility to diabetic nephropathy in North Indian population. *J Diabetes Complications* 2015; **29**: 338-342 [PMID: 25704106 DOI: 10.1016/j.jdiacomp.2015.01.002]

21 **Karban AS**, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. *Hum Mol Genet* 2004; **13**: 35-45 [PMID: 14613970 DOI: 10.1093/hmg/ddh008]

22 **Senol Tuncay S**, Okyay P, Bardakci F. Identification of NF-kappaB1 and NF-kappaBIAlpha polymorphisms using PCR-RFLP assay in a Turkish population. *Biochem Genet* 2010; **48**: 104-112 [PMID: 19941056 DOI: 10.1007/s10528-009-9302-y]

23 **American Diabetic Association**. Standards of medical care in diabetes-2015. *Diabetes Care* 2015; **38**: S1-S9

24 **Levey AS**, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; **130**: 461-470 [PMID: 10075613]

25 **James PA**, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014; **311**: 507-520 [PMID: 24352797 DOI: 10.1001/jama.2013.284427]

26 **Chen F**, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. *Clin Chem* 1999; **45**: 7-17 [PMID: 9895331]

27 **Romzova M**, Hohenadel D, Kolostova K, Pinterova D, Fojtikova M, Ruzickova S, Dostal C, Bosak V, Rychlik I, Cerna M. NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications. *Hum Immunol* 2006; **67**: 706-713 [PMID: 17002901 DOI: 10.1016/J.humimm.2006.05.006]

28 **Yang X**, Li P, Tao J, Qin C, Cao Q, Gu J, Deng X, Wang J, Liu X, Wang Z, Wu B, Gu M, Lu Q, Yin C. Association between NFKB1 -94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis. *Int J Genomics* 2014; **2014**: 612972 [PMID: 24895544 DOI: 10.1155/2014/612972]

29 **Mirza MM**, Fisher SA, Onnie C, Lewis CM, Mathew CG, Sanderson J, Forbes A. No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. *Gut* 2005; **54**: 1205-1206 [PMID: 16009698 DOI: 10.1136/gut.2005.070029]

30 **Kurylowicz A**, Hiromatsu Y, Jurecka-Lubieniecka B, Kula D, Kowalska M, Ichimura M, Koga H, Kaku H, Bar-Andziak E, Nauman J, Jarzab B, Ploski R, Bednarczuk T. Association of NFKB1 -94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease. *Genes Immun* 2007; **8**: 532-538 [PMID: 17690684 DOI: 10.1038/sj.gene.6364418]

31 **Huo ZH**, Zhong HJ, Zhu YS, Xing B, Tang H. Roles of functional NFKB1 and β-TrCP insertion/deletion polymorphisms in mRNA expression and epithelial ovarian cancer susceptibility. *Genet Mol Res* 2013; **12**: 3435-3443 [PMID: 23546975 DOI: 10.4238/2013.March.11.6]

32 **Zhou B**, Qie M, Wang Y, Yan L, Zhang Z, Liang A, Wang T, Wang X, Song Y, Zhang L. Relationship between NFKB1 -94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. *Ann Oncol* 2010; **21**: 506-511 [PMID: 19892748 DOI: 10.1093/annonc/mdp507]

33 **Thompson WL**, Van Eldik LJ. Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. *Brain Res* 2009; **1287**: 47-57 [PMID: 19577550 DOI: 10.1016/j.brainres.2009.06.081]

34 **Yang L**, Cohn L, Zhang DH, Homer R, Ray A, Ray P. Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. *J Exp Med* 1998; **188**: 1739-1750 [PMID: 9802985]

35 **Campbell IK**, Gerondakis S, O'Donnell K, Wicks IP. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. *J Clin Invest* 2000; **105**: 1799-1806 [PMID: 10862795 DOI: 10.1172/JCI8298]

36 **Hilliard B**, Samoilova EB, Liu TS, Rostami A, Chen Y. Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice: roles of NF-kappa B in the activation and differentiation of autoreactive T cells. *J Immunol* 1999; **163**: 2937-2943 [PMID: 10453042]

37 **Mohd Suzairi MS**, Tan SC, Ahmad Aizat AA, Mohd Aminudin M, Siti Nurfatimah MS, Andee ZD, Ankathil R. The functional -94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. *Cancer Epidemiol* 2013; **37**: 634-638 [PMID: 23806437 DOI: 10.1016/j.canep.2013.05.007]

38 **Li P**, Gu J, Yang X, Cai H, Tao J, Yang X, Lu Q, Wang Z, Yin C, Gu M. Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. *PLoS One* 2013; **8**: e71604 [PMID: 23977085 DOI: 10.1371/journal.pone.0071604]

**P-Reviewer:** Lehtonen SH, Sameer AS, Wada J **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 The baseline demographic and biochemical parameters in various study groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **NG****(*n* = 100)** | **DM****(*n* = 100)** | **DM-CRD****(*n* = 100)** |
| **Age** (yr) | 46.0 + 4.0 | 56.40 + 3.5 | 55.7 + 4.2 |
| **Sex ratio (**male/female) | 52/48 | 54/46 | 52/48 |
| **Duration of DM** (yr) | - | 12.7 + 1.5 | 8.1 + 2.3**d** |
| **BMI** (kg/m2) | 20.1 + 1.7 | 21.1 + 2.1 | 21.6 + 3.4 |
| **SBP** (mmHg) | 118.1 + 0.5 | 138.0 + 2.1**b** | 137.7 + 2.8 **b** |
| **DBP** (mmHg) | 75.2 + 1.0 | 81.6 + 1.9 **b** | 82.8 + 0.0 **b** |
| **Fasting glucose** (mg/dL) | 82.4 + 3.1 | 153.5 + 3.5 **b** | 184.3 + 9.2 **b, d** |
| **Postprandial glucose** (mg/dL) | 118.2 + 2.4 | 201.7 + 10.1 **b** | 261.1 + 12.2 **b, d** |
| **HbA1c** (%) | 5.11 + 0.46 | 7.10 + 0.25 **b** | 9.16 + 0.16 **b, d** |
| **Urea** (mg/dL) | 31.5 + 5.5 | 30.7 + 5.8 | 93.2 + 4.8 **b, d** |
| **Creatinine** (mg/dL) | 0.83 + 0.23 | 0.90 + 0.20 | 3.7 + 1.5 **b, d** |
| **Uric acid** (mg/dL) | 4.2 + 0.8 | 4.9 + 0.6 | 9.1 + 0.8 **b, d** |
| **eGFR** (mL/min per 1.73 m2) | 99.1 + 0.7 | 96.4 + 0.6 | 51.2 + 0.9 **d** |
| **Urinary albumin/creatinine** | - | - | 0.42 + 0.35 |

bSignificantly different from Normoglycemic at *P* < 0.001; dSignificantly different from diabetic patients without nephropathy at *P* < 0.001. Data are expressed as mean + SD. NG: Normoglycemic; DM: Diabetes mellitus without nephropathy; DM-CRD: Diabetic nephropathy; BMI: Body mass index; SBP and DBP: Systolic and diastolic blood pressure; eGFR: Estimated glomerular filtration rate.

**Table 2 The genotype and allele frequencies of *NFKB1* gene for -94 insertion/deletion ATTG polymorphism in different study groups**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **NG (*n* = 100)*****n* (%)** | **DM (*n* = 100)*****n* (%)** | **DM-CRD (*n* = 100)*****n* (%)** |
| ins/ins | 41 (41) | 38 (38) | 61 (61) |
| ins/del | 49 ( 49) | 48 (48) | 33 (33) |
| del/del | 10 (10) | 14(14) | 06**b** (06) |
| ins allele | 131 (65.5) | 124 (62) | 155 (77.5) |
| del allele | 69 (34.5) | 76 (38) | 45 (22.5) |

bSignificantly different from diabetic patients without nephropathy at *P* < 0.001. NG: Normoglycemic; DM: Diabetes mellitus without nephropathy; DM-CRD: Diabetic nephropathy.

**Table 3 Interaction analysis of -94 ins/del ATTG polymorphism with inflammatory markers**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Inflammatory marker** | **Groups** | **NG****(*n* = 100)** | **DM****(*n* = 100)** | **DM-CRD****(*n* = 100)** | ***P*-value** |
| **uMCP-1** **(pg/mg creatinine)** | **Total** | 130.00 + 42.22 | 271.00 + 120.01 | 5632.70 + 1007.20a,b |
|  | del/delins/delins/ins | 85.1 ± 9.2110.9 ± 15.6166.8 ± 26.8 | 200.6 ± 66.5278.9 ± 105.9302.2 ± 100.1 | 4609.9 ± 900.65879.9 ± 1016.36405.1 ± 1550.6 | p=0.026 |
| **Plasma TNF-α****(pg/mL)** | **Total** | 15.55 + 2.22 | 16.51 + 3.75 | 21.38 + 3.67a,b |  |
|  | del/delins/delins/ins | 8.27 + 1.0611.55 + 0.05 15.08 + 1.15  | 10.21 + 1.3214.05 + 0.18 16.36 + 1.20  | 17.31 + 1.17 19.31 + 0.44 23.12 + 0.70 | *P* = 0.030 |

uMCP-1 levels, plasma TNF-α levels are expressed as mean + SD. NG: Normoglycemic; DM: Diabetes mellitus without nephropathy; DM-CRD: Diabetic nephropathy.

**Table 4 Association between -94 ins/del ATTG polymorphism in the *NFKB1* gene and diabetic nephropathy at the genotype level**

|  |  |  |  |
| --- | --- | --- | --- |
| **Genotype** | **OR** | **95%CI** | ***P* value** |
| DM *vs* NG ref | 1.04 | 0.607-4.987 | 0.887 |
| DM-CRD *vs* NG ref | 1.95 | 1.101-3.467 | 0.022 |
| DM-CRD *vs* DM ref | 1.91 | 1.080-3.386 | 0.025 |
|  |  |  |  |

Ref: Referencegroup.

Glycemic milieu

Increase expression of NFKB1

P50

Activates IκB Kinase complex, IKK

Acts on cell membrane receptor

ROS

TNF-α

Phosphorylates IκBα and its dissociation from hetrodimer p50/p65

Nuclear translocation of NFκB (hetrodimer p50/p65)

+

NF-κB binds to promoter of genes (RelA) and promotes translation

p65

+

p50/p65

Ins allele, rs28362491 NFKB1 gene

**MCP-1**

**1**

**TNF-α**

**Diabetic Nephropathy**

**Damage to Renal tissue**

**Figure 1 *NFKB1* gene and inflammatory markers: probable mechanisms in the pathogenesis of diabetic nephropathy.** Hypeglycemia induced ROS and TNF-α leads to activation of IKK. IKK causes phosphorylation of IκBα bound to p50/p65. Phosphorylated IκBα dissociate from p50/p65 leading to nuclear translocation of unbound hetrodimer p50/p65 (NF-κB). Binding of NF-κB to promoter gene causes translation of p65. Ins allele, rs28362491 *NFKB1* gene, if present, causes increase expression of p50. Hence there is increased production of p50/p65 heterodimer complex. This heterodimer acts on its downstream proinflammatory targets *viz*: MCP-1 and TNF-α leading to its synthesis. MCP-1 is a positive regulator of TNF-α and vice versa. Both MCP-1 and TNF-α causes renal damage leading to development of Diabetic nephropathy. ROS: Reactive oxygen species; TNF-α: Tumor necrosis factor-alpha, IKK: IκB kinase complex; MCP-1: Monocyte chemoattractant protein-1.